COSA 2014* , ,
Presentations this author is a contributor to:
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-Programmed Death-1) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). (#412)
3:00 PM
Mario Sznol
Poster discussion 2
Long-term survival of ipilimumab-naïve patients with advanced melanoma (MEL) treated with nivolumab (anti-Programmed Death-1; anti-PD-1; BMS-936558; ONO-4538) in a phase I trial. (#378)
3:00 PM
Stephen Hodi
Poster discussion 2